Schonfeld Strategic Advisors’s AbCellera Biologics ABCL Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-141,295	Closed	-$493K	–	2556
2026 Q1	$493K	Buy	141,295 +121,715	+622%	+$438K	﹤0.01%	1394
2025 Q4	$67K	Buy	+19,580	New	+$87.4K	﹤0.01%	1862
2023 Q4	–	Sell	-358,400	Closed	-$1.65M	–	1828
2023 Q3	$1.65M	Buy	358,400 +211,000	+143%	+$1.28M	0.01%	880
2023 Q2	$952K	Buy	147,400 +65,500	+80%	+$447K	0.01%	999
2023 Q1	$618K	Sell	81,900 -72,900	-47%	-$662K	0.01%	1112
2022 Q4	$1.57M	Sell	154,800 -67,900	-30%	-$784K	0.01%	927
2022 Q3	$2.2M	Buy	222,700 +84,400	+61%	+$926K	0.02%	825
2022 Q2	$1.47M	Buy	138,300 +14,400	+12%	+$122K	0.01%	847
2022 Q1	$1.21M	Buy	+123,900	New	+$1.17M	0.01%	905
2021 Q4	–	Sell	-57,540	Closed	-$1.15M	–	2082
2021 Q3	$1.15M	Buy	+57,540	New	+$1.02M	0.01%	906

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Schonfeld Strategic Advisors's ABCL Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 141,295 shares — an estimated $493K sold.

Schonfeld Strategic Advisors first reported a position in ABCL in Q3 2021 and held it in 10 quarters. The position peaked at $2.2M in Q3 2022. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Schonfeld Strategic Advisors reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
Schonfeld Strategic Advisors sold 141,295 AbCellera Biologics shares in Q2 2026, an estimated $493K.
Schonfeld Strategic Advisors first reported a position in AbCellera Biologics in Q3 2021 and held it in 10 quarters.
Schonfeld Strategic Advisors's AbCellera Biologics position peaked at $2.2M in Q3 2022.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.